Company intelligence / Profile preview

Nanjing Immunofocus

Nanjing, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

The company has advanced multiple innovative immune-modulating programs into clinical development, targeting cancer, autoimmune, and neurodegenerative disorders. It aims to move two new candidates into clinical trials per year and has managed more than 30 clinical projects across several areas. Clinical results and details on lead candidates are not publicly disclosed.

Therapeutic areas: OncologyNeurologyImmunology
Modalities: Small moleculeAntibodyMonoclonal antibody
Industry: Biotech

Beyond the preview

Go deeper on Nanjing Immunofocus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanjing Immunofocus.

Explore the full profile